Form 4: United Therapeutics Director Tommy G. Thompson Acquires Stock Options
SEC Form 4 Filing
Director Tommy G. Thompson acquired 2,890 stock options in United Therapeutics Corp on July 25, 2024, as part of an annual non-employee director award.
Summary
- Tommy G. Thompson, a director of United Therapeutics Corporation, acquired 2,890 stock options on July 25, 2024.
- The transaction was an annual non-employee director award.
- The exercise price of the stock options is $336.37.
- The options vest on the one-year anniversary of the grant date, July 25, 2025, and expire on July 25, 2034.
- Following the transaction, Thompson directly owns 2,890 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to director compensation.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard Form 4 filing, which is common for corporate insiders who have transactions in their company's stock. It reflects standard compensation practices for board members.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a standard compensation practice.
Key Dates
| Date | Description |
|---|---|
| 07/25/2024 | Date of transaction: Tommy G. Thompson acquired stock options. |
| 07/25/2025 | Vesting date of the stock options. |
| 07/25/2034 | Expiration date of the stock options. |
| 07/26/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.